Purpose
To characterize the pharmacokinetics of simvastatin (SV) and simvastatin acid (SVA), a lactone–acid pair known to undergo reversible metabolism, and to better understand mechanisms underlying pharmacokinetic interactions observed between SV and gemfibrozil.
Methods
Pharmacokinetic studies were conducted after intravenous administration of SV and SVA to dogs pretreated with a vehicle or gemfibrozil. In vitro metabolism of SVA in dog hepatocytes as well as in vitro hepatic and plasma conversion of SV/SVA were investigated in the absence and presence of gemfibrozil.
Results
In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min−1 kg−1, respectively. The formation clearance of SVA from SV (CL12 = 4.8 ml min−1 kg−1) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min−1 kg−1), and the recycled fraction was relatively minor (0.009). In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min−1 kg−1, and 0.003, respectively. In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg−1) were much larger than the corresponding values of SVA (0.3 L kg−1). Gemfibrozil treatment did not affect Vss,real of either SV or SVA. In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 μM) and β-oxidative products (IC50 ∼100 μM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA β-oxidation product (IC50 = 18 μM). In in vitro dog and human liver S9 and plasma, hydrolysis of SV to SVA was much faster than that of SVA to SV. Gemfibrozil (250 μM) had a minimal inhibitory effect on the hydrolysis of either SV to SVA or SVA to SV in dog and human liver S9, but had a significant (∼60%) inhibitory effect on the SV to SVA hydrolysis in both dog and human plasma.
Conclusions
In dogs, the interconversion process favored the formation of SVA and was less efficient than the irreversible elimination processes of SV and SVA. Treatment with gemfibrozil did not affect the distribution of SV/SVA, but rather affected the elimination of SVA and the SV/SVA interconversion processes. Gemfibrozil decreased CL20 and CL21 likely via its inhibitory effect on the glucuronidation of SVA, and not on the CYP3A-mediated oxidative metabolism of SV or SVA, the β-oxidation of SVA, nor the SVA to SV hydrolysis. The decrease in CL12 might be due in part to the inhibitory effect of gemfibrozil on SV to SVA hydrolysis in plasma. Similar rationales may also be applicable to studies in humans and/or other statin lactone–acid pairs.
Abbreviations
- CLapp:
-
apparent clearance
- CLreal:
-
real clearance
- CL10:
-
irreversible elimination clearance of SV
- CL12:
-
formation clearance of SVA from SV
- CL20:
-
irreversible elimination clearance of SVA
- CL21:
-
formation clearance of SV from SVA
- SV:
-
simvastatin
- SVA:
-
simvastatin acid
- RF:
-
recycled fraction
- V ss,app :
-
apparent volume of distribution at steady state
- V ss,real :
-
real volume of distribution at steady state
References
V. F. Mauro (1993) ArticleTitleClinical pharmacokinetics and practical applications of simvastatin Clin. Pharmacokinet. 24 195–202
D. E. Duggan S. Vickers (1990) ArticleTitlePhysiological disposition of HMG-CoA-reductase inhibitors Drug Metab. Rev. 22 333–362
S. Vickers C. A. Duncan K. P. Vyas P. H. Kari B. Arison S. R. Prakash H. G. Ramjit S. M. Pitzenberger G. Stokker D. E. Duggan (1990) ArticleTitleIn vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase Drug Metab. Dispos. 18 476–483
D. G. Le Couteur P. T. Martin P. Bracs A. Black R. Hayes T. Woolf R. Stern (1996) ArticleTitleMetabolism and excretion of [14C]-atorvastatin in patients with T-tube drainage Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 3 153
M. Boberg R. Angerbauer W.K. Kanhai W. Karl A. Kern M. Radtke W. Steinke (1998) ArticleTitleBiotransformation of cerivastatin in mice, rats and dogs in vivo Drug Metab. Dispos. 26 640–652
D. W. Everett T. J. Chando G. C. Didonato S. M. Singhvi H. Y. Pan S. H. Weinstein (1999) ArticleTitleBiotransformation of pravastatin sodium in humans Drug Metab. Dispos. 19 740–748
A. E. Black R. N. Hayes B. D. Roth P. Woo T. F. Woolf (1999) ArticleTitleMetabolism and excretion of atorvastatin in rats and dogs Drug Metab. Dispos. 27 916–923
P. D. Martin M. J. Warwick A. L. Dane S. J. Hill P. B. Giles P. J. Phillips E. Lenz (2003) ArticleTitleMetabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers Clin. Ther. 25 2822–2835
T. Prueksaritanont R. Subramanian X. Fang B. Ma Y. Qiu J. H. Lin P. G. Pearson T. A. Baillie (2001) ArticleTitleGlucuronidation of statins in animals and humans: a novel mechanism of statin lactonization Drug Metab. Dispos. 30 505–512
T. Prueksaritanont L. M. Gorham B. Ma L. Liu X. Yu J. J. Zhao D. E. Slaughter B. H. Arison K. P. Vyas (1997) ArticleTitleIn vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metab. Dispos. 25 1191–1199
T. Prueksaritanont B. Ma N. Yu (2003) ArticleTitleHuman hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, not CYP2D6 Br. J. Clin. Pharmacol. 56 120–124
W. Jacobson B. Kuhn A. Soldner G. Kirchner K.-F. Sewing P. A. Kollman L. Z. Benet U. Christians (2001) ArticleTitleLactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab. Dispos. 28 1369–1378
M. Boberg R. Angerbauer P. Fey W. K. Kanhai W. Karl A. Kern J. Ploschke M. Radtke (1997) ArticleTitleMetabolism of cerivastatin by human liver microsomes in vitro: characterization of primary metabolic pathways and cytochrome P450 isozymes involved Drug Metab. Dispos. 25 321–331
D. J. Rader S. M. Haffner (1999) ArticleTitleRoles of fibrates in the management of hypertriglyceridemia Am. J. Cardiol. 83 30F–35F
A. Shek M. J. Ferrill (2001) ArticleTitleStatin–fibrate combination therapy Ann. Pharmacother. 35 908–917
J. T. Backman C. Kyrklund K. T. Kivistö J.-S. Wang P. J. Neuvonen (2000) ArticleTitlePlasma concentrations of active simvastatin acid are increased by gemfibrozil Clin. Pharmacol. Ther. 68 122–129
J. T. Backman C. Kyrklund M. Neuvonen P. J. Neuvonen (2002) ArticleTitleGemfibrozil greatly increases plasma concentrations of cerivastatin Clin. Pharmacol. Ther. 72 685–691
C. Kyrklund J. T. Backman K. T. Kivistö M. Neuvonen J. Laitila P. J. Neuvonen (2001) ArticleTitlePlasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin. Pharmacol. Ther. 69 340–345
C. Kyrklund J. T. Backman M. Neuvonen P. J. Neuvonen (2003) ArticleTitleGemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin. Pharmacol. Ther. 73 538–544
T. Prueksaritanont J. Zhao B. Ma B. A. Roadcap C. Tang Y. Qiu L. Liu J. H. Lin P. G. Pearson T. A. Baillie (2002) ArticleTitleMechanistic studies on the metabolic interactions between gemfibrozil and statins J. Pharmacol. Exp. Ther. 301 1042–1051
J. J. DiStefano (1976) ArticleTitleConcepts, properties, measurement, and computation of clearance rates of hormones and other substances in biological systems Ann. Biomed. Eng. 4 302–319
J. G. Wagner A. R. DiSanto W. R. Gillespie K. S. Albert (1981) ArticleTitleReversible metabolism and pharmacokinetics: Application to prednisone and prednisolone Res. Commun. Chem. Pathol. Pharmacol. 32 387–405
W. F. Ebling W. J. Jusko (1986) ArticleTitleThe determination of essential clearance, volume, and residence time parameters of recirculating metabolic systems: the reversible metabolism of methylprednisolone and methylprednisone in rabbits J. Pharmacokin. Biopharm. 14 557–599
T. Prueksaritanont C. Tang Y. Qiu L. Mu R. Subramanain J. H. Lin (2002) ArticleTitleEffects of fibrates on metabolism of statins in human hepatocytes Drug Metab. Dispos. 30 1280–1287
H. Schulz (1987) ArticleTitleInhibitors of fatty acid oxidation Life Sci. 40 1443–1449
T. Prueksaritanont, K. M. Richards, Y. Qiu, K. Strong-Basalyga, A. Miller, C. Li, R. Eisenhandler, and E. J. Carlini. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm. Res. 22:71–78 (2005).
C. Hamberger J. Barre R. Zini A. Taiclet G. Houin J. P. Tillement (1986) ArticleTitleIn vitro binding study of gemfibrozil to human serum proteins and erythrocytes: interactions with other drugs Int. Clin. Pharm. Res. 6 441–449
M. G. Soars B. Burchell R. J. Riley (2002) ArticleTitleIn vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance J. Pharmacol. Exp. Ther. 301 382–390
R. A. Okerholm F. J. Keeley F. E. Peterson A. J. Glazko (1976) ArticleTitleThe metabolism of gemfibrozil Proc. R. Soc. Med. 69 IssueIDSuppl. 2 11–14
S. Yoshihisa M. Hirano H. Satao Y. Sugiyama (2004) ArticleTitleGemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil J. Pharmacol. Exp. Ther. 311 228–236
J. L. Lam L. Z. Benet (2004) ArticleTitleHepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug–drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes Drug Metab. Dispos. 32 1311–1316
B. Hsiang Y. Zhu Z. Wang Y. Wu V. Sasseville W.-P. Yang T. G. Kirchgessner (1999) ArticleTitleA novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters J. Biol. Chem. 274 37161–37168
J. H. Hochman N. T. Pudvah Y. Qiu M. Yamazaki C. Tang J. H. Lin T. Prueksaritanont (2004) ArticleTitleInteractions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin Pharm. Res. 21 1688–1693
M. Yamazaki, B. Li, S. W. Louie, N. T. Pudvah, R. Stocco, W. Wong, M. Abramovitz, A. Demartis, R. Laufer, J. H. Hochman, T. Prueksaritanont, and J. H. Lin. Effects of fibrates on human organic anion-transporting polypeptide 1B1 (OATP2, OATP-C, SLC21A6)-, multidrug resistance protein 2 (MRP2/ABCC2)-, and P-glycoprotein (ABCB1)-mediated transport. Xenobiotica in press.
A. J. Bergman G. Murphy J. Burke J. J. Zhao R. Valesky L. Liu K. C. Lasseter W. He T. Prueksaritanont Y. Qiu A. Hartford J. M. Vega J. F. Paolini (2004) ArticleTitleSimvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans J. Clin. Pharmacol. 44 1054–1062
Acknowledgments
We thank Ms. Y. Meng and Mr. Bennett Ma for analysis of plasma samples and Kristie Strong-Basalyga for assistance in hepatocyte isolation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prueksaritanont, T., Qiu, Y., Mu, L. et al. Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil. Pharm Res 22, 1101–1109 (2005). https://doi.org/10.1007/s11095-005-6037-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-005-6037-2